Clinical trial

Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

NCT07357103

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Clindamycin + primaquine Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pentamidine Normalized identity: pentamidineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Atovaquone Normalized identity: atovaquoneView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-03-01

PhasePHASE4

Conditions

Pneumocystisverified · MONDO: pneumocystosis

Pneumocystis Infectionverified · MONDO: Pneumocystis infectious disease

Pneumocystis Carinii Infectionunresolved

Pneumocystis Carinii; Infection, Resulting From HIV Diseaseunresolved

Pneumocystis Jirovecii Pneumoniaverified · MONDO: pneumocystosis

Pneumocystis Jirovecii Infectionunresolved

Pneumocystosis Associated With AIDSunresolved

Pneumocystosis; Pneumonia (Etiology)unresolved

Interventions

Clindamycin + primaquineDRUG

PentamidineDRUG · verified · RxNorm: pentamidine

AtovaquoneDRUG · verified · RxNorm: atovaquone

Sponsors & collaborators

McGill University Health Centre/Research Institute of the McGill University Health Centrelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07357103 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.